TY - JOUR
T1 - Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C
AU - Ikegami, Toru
AU - Wang, Huanlin
AU - Yoshizumi, Tomoharu
AU - Toshima, Takeo
AU - Aishima, Shinichi
AU - Fukuhara, Takasuke
AU - Furusyo, Norihiro
AU - Kotoh, Kazuhiro
AU - Shimoda, Shinji
AU - Shirabe, Ken
AU - Maehara, Yoshihiko
N1 - Funding Information:
Acknowledgements The authors thank Takako Shishino, Junko Eguchi, and Hideyuki Konishi for their excellent technical assistance. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor, and Welfare of Japan.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2014/4
Y1 - 2014/4
N2 - Purpose: Interferon-induced graft dysfunction (IGD) is a poorly defined, unrecognized, but potentially serious condition for patients receiving antiviral drugs after liver transplantation for hepatitis C. Methods: We evaluated the characteristics of 80 patients who received pegylated interferon-based antiviral treatment for hepatitis C after living donor liver transplantation (LDLT). Results: Eight patients experienced IGD either during (n = 6) or after completing (n = 2) antiviral treatment. Pathological diagnosis included acute cellular rejection (ACR, n = 1), plasma cell hepatitis (PCH, n = 2), PCH plus ACR (n = 3), and chronic rejection (CR, n = 2). One patient with CR initially presented with PCH plus ACR and the other presented with ACR; both had apparent cholestasis. The six patients with ACR or PCH without cholestasis were successfully treated by discontinuing antiviral treatment and increasing immunosuppression, including steroids. By contrast, both of the patients with CR and cholestasis experienced graft loss, despite aggressive treatment. Univariate analysis showed that pegylated interferon-α2a-based treatment (75 vs. 26.4 %, p < 0.01) was the only significant factor for IGD, and was associated with decreased 5-year graft survival (93.4 vs. 71.4 %, p = 0.04). Conclusions: IGD is a serious condition during or even after antiviral treatment for hepatitis C after LDLT. Early recognition, diagnosis, discontinuation of interferon, and introduction of steroid-based treatment may help to save the graft.
AB - Purpose: Interferon-induced graft dysfunction (IGD) is a poorly defined, unrecognized, but potentially serious condition for patients receiving antiviral drugs after liver transplantation for hepatitis C. Methods: We evaluated the characteristics of 80 patients who received pegylated interferon-based antiviral treatment for hepatitis C after living donor liver transplantation (LDLT). Results: Eight patients experienced IGD either during (n = 6) or after completing (n = 2) antiviral treatment. Pathological diagnosis included acute cellular rejection (ACR, n = 1), plasma cell hepatitis (PCH, n = 2), PCH plus ACR (n = 3), and chronic rejection (CR, n = 2). One patient with CR initially presented with PCH plus ACR and the other presented with ACR; both had apparent cholestasis. The six patients with ACR or PCH without cholestasis were successfully treated by discontinuing antiviral treatment and increasing immunosuppression, including steroids. By contrast, both of the patients with CR and cholestasis experienced graft loss, despite aggressive treatment. Univariate analysis showed that pegylated interferon-α2a-based treatment (75 vs. 26.4 %, p < 0.01) was the only significant factor for IGD, and was associated with decreased 5-year graft survival (93.4 vs. 71.4 %, p = 0.04). Conclusions: IGD is a serious condition during or even after antiviral treatment for hepatitis C after LDLT. Early recognition, diagnosis, discontinuation of interferon, and introduction of steroid-based treatment may help to save the graft.
UR - http://www.scopus.com/inward/record.url?scp=84899949344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899949344&partnerID=8YFLogxK
U2 - 10.1007/s12072-013-9496-2
DO - 10.1007/s12072-013-9496-2
M3 - Article
AN - SCOPUS:84899949344
SN - 1936-0533
VL - 8
SP - 285
EP - 292
JO - Hepatology International
JF - Hepatology International
IS - 2
ER -
